^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SQZ-AAC-HPV

    i
    Other names: SQZ-AAC-HPV
    Company:
    STEMCELL Technologies
    Drug class:
    Immunomodulator
    Related drugs:
    10ms
    ENVOY-001: Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=5, Terminated, SQZ Biotechnologies | N=72 --> 5 | Trial completion date: Apr 2024 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Nov 2023; Corporate Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SQZ-AAC-HPV
    almost2years
    ENVOY-001: Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, SQZ Biotechnologies | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Checkpoint inhibition • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SQZ-AAC-HPV
    almost2years
    ENVOY-001: Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, SQZ Biotechnologies | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Checkpoint inhibition • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SQZ-AAC-HPV
    almost3years
    ENVOY-001: A phase 1, multicenter, open-label study of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors. (AACR 2022)
    Murine AAC-HPV treatment was also shown to be synergistic with cisplatin combinations...The second part of the study will assess the safety of SQZ-AAC-HPV when combined with nivolumab 360 mg q3w and/or ipilimumab 3 mg/kg q3w x4 or 1 mg/kg q6w when combined with nivolumab... N/A
    Clinical • P1 data • Combination therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma)
    |
    HLA-A*02
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • SQZ-AAC-HPV
    over3years
    Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, SQZ Biotechnologies | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • Checkpoint inhibition
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SQZ-AAC-HPV